Your session is about to expire
← Back to Search
Eblasakimab for Eczema
Study Summary
This trial will test a new drug to treat moderate-to-severe atopic dermatitis. It will last 24 weeks with randomized treatment and placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My doctor is concerned about my organ function or lab results.I am 18 years old or older.I do not have active tuberculosis or it has been adequately treated.I have recently been treated with experimental drugs.I have been treated with dupilumab under specific conditions.I have had chronic eczema for at least one year.I haven't used any immune-altering drugs or therapies, including JAK inhibitors or phototherapy, in the last 4 weeks.I have used certain skin medications recently.I am HIV positive or have a history of HIV.I am infected with hepatitis B or C.I currently have an active COVID-19 infection.At least 10% of my skin is affected by my condition.My skin condition didn't improve with standard creams or I couldn't tolerate them.I have liver cirrhosis or chronic hepatitis.I frequently use steroids for a chronic condition.My asthma has required strong medication or hospital visits in the last year.I have been treated with dupilumab before.I've had a bad reaction or no improvement from eczema creams.
- Group 1: Placebo
- Group 2: ASLAN004
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What assurances can be made regarding the safety of ASLAN004?
"ASLAN004 has been granted a safety score of 2; while there is some evidence that it is safe to use, no data exists yet demonstrating its efficacy."
Are any new participants being accepted for this research project?
"Clinical trials.gov reports that this trial is still in search of participants; the initial posting was made on December 21st 2022 and updated most recently on January 20th 2023."
What is the maximum participant capacity for this trial?
"Indeed, the records posted on clinicaltrials.gov affirms that this medical trial is actively recruiting patients. It was initially published on December 21st 2022 and later revised on January 20th 2023. The research team seeks to enroll 75 participants from a single site."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger